Zum Inhalt

Gastric and esophageal cancer: Post ASCO 2015

  • 01.12.2015
  • short review
Erschienen in:

Abstract

Immunologic tumor therapy was the leading theme of this year’s ASCO. In this context first results for check point inhibitors active in esophageal and gastric cancer were presented. Phase III trials involving c-met inhibitors however were not successful. First phase II results with regorafenib emphasize a potential role for TKI’s in gastric cancer.
Titel
Gastric and esophageal cancer: Post ASCO 2015
Verfasst von
Ewald Wöll, MD
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0227-3
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.